Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Debt: 2023-2025

Historic Total Debt for Spyre Therapeutics (SYRE) over the last 3 years, with Sep 2025 value amounting to $11.0 million.

  • Spyre Therapeutics' Total Debt fell 55.46% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 55.46%. This contributed to the annual value of $25.1 million for FY2024, which is 1704.32% up from last year.
  • Spyre Therapeutics' Total Debt amounted to $11.0 million in Q3 2025, which was down 81.60% from $59.9 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Total Debt peaked at $164.4 million during Q2 2023, and registered a low of $1.4 million during Q4 2023.
  • For the 3-year period, Spyre Therapeutics' Total Debt averaged around $34.2 million, with its median value being $17.9 million (2024).
  • Per our database at Business Quant, Spyre Therapeutics' Total Debt slumped by 98.39% in 2024 and then spiked by 2,168.94% in 2025.
  • Quarterly analysis of 3 years shows Spyre Therapeutics' Total Debt stood at $1.4 million in 2023, then spiked by 1,704.32% to $25.1 million in 2024, then slumped by 55.46% to $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $59.9 million for Q2 2025, and $42.8 million during Q1 2025.